Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours
Éric Raymond(Hôpital Paris Saint-Joseph), Nicola Fazio(European Institute of Oncology), Mustafa Khasraw(The University of Sydney), Chigusa Morizane(Tokyo National Hospital), Jozef Šufliarský(Comenius University Bratislava), Paul E. Oberstein(Columbia University Irving Medical Center), Matthew H. Kulke(Brigham and Women's Hospital), Paul Ruff, Jiří Tomášek(Masaryk Memorial Cancer Institute), Michael Schenker(Sorbonne Université), Reza Khosravan(Pfizer (United States)), Brad Rosbrook(Pfizer (United States)), Shailesh V. Shrikhande(Homi Bhabha National Institute), Espen Thiis‐Evensen(Oslo University Hospital), Shukui Qin(Sichuan University), Eva Sedláčková, Gazala Khan(Henry Ford Health System), Pascal Hammel(Université Paris Cité), Salvatore Galdy(European Institute of Oncology), Lin Shen(Peking University), Tetsuhide Ito, Xianjun Yu(Hubei University of Medicine), Jian-Ming Xu(Academy of Military Medical Sciences), Yali Shen(Sichuan University), Wenhui Lou(Fudan University), Liqun Jia(China-Japan Friendship Hospital), Adina Croitoru(Institutul Clinic Fundeni), Antonio Cubillo(Hospital Universitario HM Sanchinarro), Kathrine C. Fernandez(Pfizer (United States)), Ivan Borbath
Cited by 55
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k